Abstract
(Abstracted from Lancet Glob Health 2021;9:e1119–e1128) Hypertension in pregnancy (HIP) has served as a marker for increased risk of adverse pregnancy outcomes, including fetal growth restriction, stillbirth, severe maternal morbidity, and maternal mortality. Traditionally, HIP has been defined as systolic blood pressure (sBP) of ≥140 mm Hg, diastolic BP (dBP) of ≥90 mm Hg, or both.
Highlights
Hypertension in pregnancy has traditionally been defined as a systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg, or both.[1]
Implications of all the available evidence Our findings suggest that there is an association between the American College of Cardiology and American Heart Association blood pressure thresholds and adverse pregnancy outcomes in low-income and middle-income countries (LMICs) settings, but there is no antenatal blood pressure threshold that is sensitive with regards to the adverse maternal, fetal, or neonatal outcomes studied, including datadriven cutoffs
More than one-quarter of women had abnormal blood pressure classified as elevated blood pressure (2196 [10·4%] of 21 069) or non-severe stage 1 hyperten sion (3751 [17·8%])
Summary
Hypertension in pregnancy has traditionally been defined as a systolic blood pressure (sBP) of at least 140 mm Hg or a diastolic blood pressure (dBP) of at least 90 mm Hg, or both.[1]. Hypertension defined in this way identifies pregnant women at increased risk of pre-eclampsia and other maternal and fetal or neonatal complications, including death, and these women are recommended to receive enhanced antenatal care and monitoring worldwide.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
